Close Menu

NEW YORK (GenomeWeb) – 23andMe today announced it has raised $115 million in a Series E financing round that will go toward expanding the company's operations and "maximize the potential of its direct-to-consumer product in the US and abroad." 

Fidelity Management & Research led the financing and was joined by new investors Casdin Capital, WuXi Healthcare Ventures, and Xfund. Existing investors Illumina, New Enterprise Associates, MPM Capital, and Google Ventures also participated in the round. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.